Remove ACE Inhibitor Remove Kidney Disease Remove Research
article thumbnail

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. Researchers tracked outcomes for a median of just under 18 months. The study’s primary composite endpoint occurred in 8.2% of those who received empagliflozin and 9.1%

article thumbnail

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. Researchers tracked outcomes for a median of just under 18 months. 24, being held in Atlanta, GA. The study’s primary composite endpoint occurred in 8.2% of those who received empagliflozin and 9.1%